Analyst
Bloom Burton
Equibles does not estimate personal net worth.
David Martin is recorded as Analyst at Bloom Burton. David Martin has spoken on 1 earnings call across 1 company, most recently for Knight Therapeutics Inc. on November 5, 2026. The companies whose calls David Martin spoke on are classified in the Healthcare sector.
“I'm just wondering, were there any sales of Ambizone to the Brazilian MOH this quarter or in Q3? And regarding the generic approval, has the 2027 MOH contract gone to the generic?”
Bloom Burton
Analyst
Transcript header (unverified)
Knight Therapeutics Inc.
Drug Manufacturers - Specialty & Generic · Healthcare
Knight Therapeutics' Third Quarter 2026 Results Conference Call
Knight Therapeutics Inc.
